Vutrisiran sodium
As of the edition of 20 October 2026, Vutrisiran sodium is an oligonucleotide: marketed, first approved in 2022 (US); acts on TTR; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Oligonucleotide
- Brand name
- Amvuttra
- First approved
- 13 June 2022 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Alnylam Pharmaceuticals; 2 holders in all
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by Alnylam Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product17 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 17 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TTR | Transthyretin | P02766 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alnylam Pharmaceuticals | Originator and Applicant | 2022 to now |